The U.S. Food & Drug Administration (FDA) recently adopted changes to the approvals of two medications for inflammatory skin diseases. Ebglyss (lebrikizumab-lbkz) has a newly approved regimen of one maintenance dose every eight weeks of a single injection (250mg/2mL) in adults and children 12 years of age and older with moderate-to-severe atopic dermatitis and who weigh at least 88 pounds. In addition, starting with prescription topicals is no longer required.
“This new dosing regimen without mandatory topicals gives patients a new option to manage their condition based on individual needs. It’s about meeting patients where they are in their lives,” says Peter Lio, MD, clinical assistant professor of dermatology and pediatrics at Northwestern University Feinberg School of Medicine.
In addition, the FDA expanded the label of Tremfya (guselkumab) to note the inhibition of progression of structural joint damage in adults with active psoriatic arthritis. Tremfya is now the only IL-23 inhibitor proven to help stop further structural damage.
“Joint damage associated with active psoriatic arthritis can happen as soon as six months afteronset of disease, so it's important to have treatment solutions that can help provide daily symptom relief while also protecting joints from long-term structural damage” said Philip J. Mease, MD, clinical professor at the University of Washington School of Medicine.
UCB Launches Scholarship Fund for Those Affected by Hidradenitis Suppurativa
Applications are open for the new UCB Hidradenitis Suppurativa Scholarship Program, designed to support adults age 18 and older living with hidradenitis suppurativa (HS), and their immediate family members. UCB will award up to 11 scholarships for education and career development, such as undergraduate or graduate studies and trade school. In a news release, the company notes HS can significantly impact a person’s quality of life, including their work and schooling.
“This community is made up of people who are resilient, inspired, and incredibly driven” said Rhonda Peebles, UCB head of U.S. dermatology. "With the UCB Hidradenitis Suppurativa Scholarship Program, we are proud to be investing in the goals of people living with HS and their families, and opening up opportunities when they may have needed to prioritize navigating the challenges of HS over their education or career.”
Applications close September 1.
American Skin Association Presents Award to Sun Pharma
The American Skin Association named Sun Pharma recipient of the 2026 Corporate Leadership Award.
“Sun Pharma shares our dual mission of research and education, and we very much look forward to working together to find cures for skin diseases,” says Howard P. Milstein, ASA chairman. Through a Sun Pharma educational grant, the ASA recently launched a patient-facing podcast series — SkinSight Podcast — that explains common skin conditions, addresses real patient experiences, and offer advice from dermatology experts.
